Signals, Powered By EquityPandit
On Tuesday, Jubilant Life Science said that it has received the US health regulator’s approval for its generic version of Merck’s acute migraine treatment medicine, Maxalt-MLT.
The company said in a BSE filing that it has got Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Rizatriptan Benzoate orally disintegrating tablets, 5 mg and 10 mg.
It further said that the medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck which is indicated for the acute treatment of migraine in adults and paediatric patients.
